Intended for healthcare professionals


Erythropoietin stimulating agents do not significantly improve quality of life in chronic kidney disease, study finds

BMJ 2016; 352 doi: (Published 16 February 2016) Cite this as: BMJ 2016;352:i931
  1. Michael McCarthy,
  2. Seattle

Treating chronic kidney disease more intensively with erythropoietin stimulating agents (ESAs) to achieve higher haemoglobin levels did not improve patients’ quality of life, a meta-analysis published in the Annals of Internal Medicine has shown.1

ESAs are often used to raise haemoglobin levels in patients with chronic kidney disease, but optimal haemoglobin levels are debated, particularly because of …

View Full Text

Log in

Log in through your institution


* For online subscription